Multisite reproducibility of the broth microdilution method for susceptibility testing of Nocardia species

Journal of Clinical Microbiology

Volumn 50, Issue 4, 2012, Pages 1270-1280

  Conville, Patricia S ^a,i   Brown Elliott, Barbara A ^c   Wallace, Richard J ^c   Witebsky, Frank G ^a   Koziol, Deloris ^b   Hall, Geraldine S ^d   Killian, Scott B ^e   Knapp, Cindy C ^e   Warshauer, David ^f   Van, Tam ^f   Wengenack, Nancy L ^g   Deml, Sharon ^g   Woods, Gail L ^h  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c UNIVERSITY OF TEXAS HEALTH CENTER   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

^e Thermo Fisher Scientific   (United States)

^f WISCONSIN STATE LABORATORY OF HYGIENE   (United States)

^g MAYO CLINIC   (United States)

^h CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

ⁱ CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; CEFTRIAXONE; CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; IMIPENEM; LINEZOLID; MINOCYCLINE; MOXIFLOXACIN; SULFAFURAZOLE; SULFAMETHOXAZOLE; SULFONAMIDE; TIGECYCLINE; TOBRAMYCIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BROTH DILUTION; CONTROLLED STUDY; DISK DIFFUSION; MINIMUM INHIBITORY CONCENTRATION; NOCARDIA; NOCARDIA BRASILIENSIS; NOCARDIA CYRIACIGEORGICA; NOCARDIA FARCINICA; NOCARDIA NOVA; NOCARDIA WALLACEI; NONHUMAN; PRIORITY JOURNAL; QUALITY CONTROL; REPRODUCIBILITY;

NOCARDIA; NOCARDIA BRASILIENSIS; NOCARDIA CYRIACIGEORGICA; NOCARDIA FARCINICA; NOCARDIA NOVA; NOCARDIA SP.;

EID: 84857399596     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.00994-11     Document Type: Article

References (19)

1. Brown-Elliott BA, et al. 14 December 2011, posting date. Sulfonamide resistance in isolates of Nocardia from a United States multicenter survey. J. Clin. Microbiol. [Epub ahead of print.] doi:10.1128/JCM.06243-11.
2. Brown-Elliott BA, Brown JM, Conville PS, Wallace RJ, Jr. 2006. Clinical and laboratory features of the Nocardia spp. based on current molecular taxonomy. Clin. Microbiol. Rev. 19:259 -282.
3. CLSI. 2009. Performance standards for antimicrobial disk susceptibility tests: approved standard, 10th ed. CLSI document M02-A10. Clinical and Laboratory Standards Institute, Wayne, PA.
4. CLSI. 2010. Performance standards for antimicrobial susceptibility testing: twentieth informational supplement. CLSI document M100-S20. Clinical and Laboratory Standards Institute, Wayne, PA.
5. CLSI. 2011. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes. CLSI document M24-A2. Clinical and Laboratory Standards Institute, Wayne, PA.
6. CLSI. 2003. Susceptibility testing of mycobacteria, nocardiae and other aerobic actinomycetes. CLSI document M24-A. Clinical and Laboratory Standards Institute, Wayne, PA.
7. Conville PS, et al. 2003. Nocardia veterana as a pathogen in North American patients. J. Clin. Microbiol. 41:2560-2568. (Pubitemid 36712468)
8. Conville PS, Zelazny AM, Witebsky FG. 2006. Analysis of secA1 gene sequences for identification of Nocardia species. J. Clin. Microbiol. 44:2760-2766. (Pubitemid 44228568)
9. Gomez-Flores A, et al. 2004. In vitro and in vivo activities of antimicrobials against Nocardia brasiliensis. Antimicrob. Agents Chemother. 48:832-837. (Pubitemid 38280332)
10. Ishikawa J, et al. 2004. The complete genomic sequence of Nocardia farcinica IFM 10152. Proc. Natl. Acad. Sci. U. S. A. 101:14925-14930. (Pubitemid 39410776)
11. Laurent F, et al. 1999. Biochemical-genetic analysis and distribution of FAR-1, a classAβ-lactamase from Nocardia farcinica. Antimicrob. Agents Chemother. 43:1644 -1650.
12. Sorrell TC, Mitchell DH, Iredell JR, Chen SCA. 2010. Nocardia species, p 3199-3207. In Mandell GL, Bennett JE, Dolin R (ed), Mandell, Douglas and Bennett's principles and practice of infectious diseases, 7th ed, vol 2. Churchill Livingstone, Philadelphia, PA.
13. Steingrube VA, et al. 1993. Partial characterization of Nocardia farcinica β-lactamases. Antimicrob. Agents Chemother. 37:1850 -1855.
14. Uhde KB, et al. 2010. Antimicrobial-resistant Nocardia isolates, United States, 1995-2004. Clin. Infect. Dis. 51:1445-1448.
15. Wallace RJ, Jr, Nash DR, Johnson WK, Steele LC, Steingrube VA. 1987. β-Lactam resistance in Nocardia brasiliensis is mediated by β-lactamase and reversed in the presence of clavulanic acid. J. Infect. Dis. 156:959 -966.
16. Wallace RJ, Jr, Brown BA, Tsukamura M, Brown JM, Onyi GO. 1991. Clinical and laboratory features of Nocardia nova. J. Clin. Microbiol. 29: 2407-2411.
17. Wallace RJ, Jr, Steele L. 1988. Susceptibility testing of Nocardia species for the clinical laboratory. Diagn. Microbiol. Infect. Dis. 9:155-166.
18. Wallace RJ, Jr, et al. 1990. Cefotaxime-resistant Nocardia asteroides strains are isolates of the controversial species Nocardia farcinica. J. Clin. Microbiol. 28:2726 -2732.
19. Wilson RW, et al. 1997. Recognition of a Nocardia transvalensis complex by resistance to aminoglycosides, including amikacin, and PCRrestriction fragment length polymorphism analysis. J. Clin. Microbiol. 35:2235-2242. (Pubitemid 27349788)